Global High-intensity Focused Ultrasound Therapy Market Research Report 2024-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2030

Global High-intensity Focused Ultrasound Therapy Market Research Report 2024-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2030

High-intensity focused ultrasound therapy uses the physical characteristics of ultrasound, such as directionality, focalization and penetrability, to focus on the diseased tissue in vivo through a focusing transducer, so that the target tissue is irreversibly coagulated and necrotic due to protein degeneration, while the tissues outside the target area are hardly damaged, thus achieving the purpose of non-invasive treatment. At present, high-intensity focused ultrasound therapy can be used to treat benign and malignant solid tumors, and it is a non-invasive and green treatment technology with broad development prospects.

Market Overview:

The latest research study on the global High-intensity Focused Ultrasound Therapy market finds that the global High-intensity Focused Ultrasound Therapy market reached a value of USD 196.79 million in 2023. It’s expected that the market will achieve USD 471.41 million by 2029, exhibiting a CAGR of 15.67% during the forecast period.

Market challenges and constraints

Dose control problems in high-intensity focused ultrasound therapy
Currently, high-intensity focused ultrasound therapy is regarded as one of the most promising new methods of non-invasive tumor treatment. The basic principle is: using the sound focusing effect, low-energy ultrasound outside the body is focused on the lesion area in the biological medium, so that the temperature of the treatment area rises to above 65°C in a short time, thereby causing coagulation necrosis of the diseased tissue and maximizing the It does not damage other normal tissues around the tumor, thereby achieving minimally invasive or even non-invasive treatment. Focused ultrasound dose control is the prerequisite to ensure the efficiency and safety of high-intensity focused ultrasound treatment. It is also a key issue that needs to be solved and studied in depth in the current field of high-intensity focused ultrasound treatment. The dosage of the treatment affects the final treatment result. If the treatment dose is too small, it will lead to incomplete tissue ablation. If the treatment dose is too large, it will lead to increased patient discomfort and the risk of complications. Acoustic focus and temperature control are important foundations for dose control. Currently, the dosage control method in the prior art is to rely on the doctor's experience and subjective judgment to set the treatment dosage before treatment. During treatment, the treatment dose is adjusted through the use of real-time image monitoring. Currently, commonly used image monitoring includes ultrasound monitoring and MRI monitoring. Ultrasound monitoring relies on the presence of mass hyperechoic changes in the target area or a significant increase in overall grayscale. However, there may be situations where the grayscale changes are not obvious during the treatment process, making it impossible for doctors to accurately judge the actual condition of the tissue from ultrasound monitoring. Although MRI monitoring has the advantages of high tissue contrast and non-destructive temperature monitoring during treatment, the method of using MRI monitoring to adjust the treatment dose has a certain lag, making it impossible for doctors to know the actual condition of the tissue in a timely manner. The problem of dose control in high-intensity focused ultrasound therapy is one of the challenges facing development.

High-intensity focused ultrasound therapy is widely used in clinical practice

High-intensity focused ultrasound therapy is widely used in clinical practice
At present, on the one hand, due to factors such as the aging population, high life pressure, irregular work and rest, and eating habits, the number of patients with liver tumors, breast cancer, breast fibroadenoma, prostate cancer, and uterine fibroids is increasing. At the same time, with the continuous improvement of the economy, people's expenditures in the medical field have increased, and the market demand for high-quality and highly effective treatment services has increased. High-intensity focused ultrasound therapy, as a non-invasive and safe treatment method with broad development prospects, has been widely used in malignant tumors and benign diseases. In general, the widespread clinical application of high-intensity focused ultrasound therapy has actively promoted market development.

Region Overview:

In 2022, the share of the High-intensity Focused Ultrasound Therapy market in Asia-Pacific stood at 38.26%.

Company Overview:

Insightec was founded by GE Healthcare and Elbit Medical Imaging in 1999 to bring MRI-guided focused ultrasound to the market. Exablate Neuro and Exablate Body systems can be used in conjunction with GE's series of MR systems to treat idiopathic tremor, Parkinson's disease with tremor as the main symptom, symptomatic hysteromyoma and pain relief of bone metastasis. In December, 2020, Insightec and Royal Philips announced the cooperation in developing the compatibility between Exablate Neuro platform and Philips advanced MR system.

Founded in 1999, Chongqing Haifu Medical Technology Co., Ltd. is a service provider of medical equipment and comprehensive solutions focusing on basic research, equipment development, manufacturing, clinical programs, training support, marketing and after-sales service in the field of ultrasound therapy. It is a national high-tech enterprise, a national innovative enterprise and a national intellectual property demonstration enterprise, and has platforms such as an international scientific and technological cooperation base and enterprise Post-Doctoral Research Center. Haifu Medical has increased its clinical application, and China's original technology and large-scale medical equipment have gone global, occupying a global market advantage. After more than 20 years of technical research and development and industrial development, Haifu Medical has developed three series of high-end medical equipment with more than ten models for focused ultrasound treatment of benign and malignant tumors, common diseases and rehabilitation care, and has obtained market access certificates from more than 40 countries and regions such as NMPA registration certification in China and CE registration certification in the European Union. Haifu knife equipment has been exported to Britain, Spain, Russia, Saudi Arabia, Germany, Cuba, South Africa, Argentina, South Korea and other 30 countries and regions.

Insightec is one of the major players operating in the High-intensity Focused Ultrasound Therapy market, holding a share of 34.09% in 2023.

Segmentation Overview:

By type, MRgFUS segment accounted for the largest share of market in 2022.

Application Overview:

By application, the Prostate cancer and benign prostate diseases segment occupied the biggest share from 2018 to 2022.

Key Companies in the global High-intensity Focused Ultrasound Therapy market covered in Chapter 3:

Shanghai A&S Science Technology co.,ltd
Theraclion
Beijing Yuande Biomedical Engineering Co., Ltd.
Shanghai A & S Science Technology Development Co.,Ltd
Profound Medical
Sonablate
Cardiawave
Insightec
EDAP TMS
Chongqing Haifu Medical Technology Co., Ltd.

In Chapter 4 and Chapter 14.2, on the basis of types, the High-intensity Focused Ultrasound Therapy market from 2019 to 2030 is primarily split into:

Non-invasive Treatment
Minimal Invasive Treatment

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the High-intensity Focused Ultrasound Therapy market from 2019 to 2030 covers:

Liver tumor
Breast cancer and breast fibroadenoma
Prostate cancer and benign prostate diseases
Hysteromyoma
Other

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2019-2030) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)